AGF Investments Inc. cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 145,336 shares of the medical research company’s stock after selling 4,439 shares during the quarter. AGF Investments Inc.’s holdings in Thermo Fisher Scientific were worth $39,781,000 as of its most recent filing with the Securities and Exchange Commission.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. AGF Investments America Inc. grew its holdings in shares of Thermo Fisher Scientific by 2.0% during the 1st quarter. AGF Investments America Inc. now owns 58,394 shares of the medical research company’s stock worth $15,984,000 after purchasing an additional 1,165 shares during the period. Hunter Associates Investment Management LLC grew its holdings in shares of Thermo Fisher Scientific by 2.1% during the 1st quarter. Hunter Associates Investment Management LLC now owns 13,412 shares of the medical research company’s stock worth $3,671,000 after purchasing an additional 280 shares during the period. Lockheed Martin Investment Management Co. purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $6,232,000. Zions Bancorporation N.A. purchased a new position in shares of Thermo Fisher Scientific during the 1st quarter worth $983,000. Finally, O Shaughnessy Asset Management LLC grew its holdings in shares of Thermo Fisher Scientific by 23.6% during the 1st quarter. O Shaughnessy Asset Management LLC now owns 19,211 shares of the medical research company’s stock worth $5,258,000 after purchasing an additional 3,666 shares during the period. Institutional investors and hedge funds own 87.96% of the company’s stock.
Shares of Thermo Fisher Scientific stock opened at $285.22 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $202.83 and a 12 month high of $288.07. The stock has a market cap of $113.70 billion, a P/E ratio of 25.65, a PEG ratio of 1.85 and a beta of 1.08. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.69 and a quick ratio of 1.16.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $2.81 EPS for the quarter, beating analysts’ consensus estimates of $2.74 by $0.07. Thermo Fisher Scientific had a return on equity of 17.06% and a net margin of 12.89%. The company had revenue of $6.13 billion during the quarter, compared to analysts’ expectations of $6.04 billion. During the same period last year, the business posted $2.50 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 4.6% on a year-over-year basis. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 12.2 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 16th. Investors of record on Friday, June 14th will be issued a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Thursday, June 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 6.83%.
A number of equities analysts have recently weighed in on the company. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, May 6th. BTIG Research increased their price target on Thermo Fisher Scientific to $310.00 and gave the stock a “buy” rating in a report on Tuesday, March 26th. Argus increased their price target on Thermo Fisher Scientific from $285.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Needham & Company LLC restated a “strong-buy” rating and set a $315.00 target price (up from $313.00) on shares of Thermo Fisher Scientific in a report on Thursday, May 23rd. Finally, Bank of America restated a “buy” rating and set a $300.00 target price (up from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $295.92.
In other Thermo Fisher Scientific news, Director C Martin Harris sold 275 shares of the stock in a transaction dated Wednesday, June 5th. The stock was sold at an average price of $270.73, for a total value of $74,450.75. Following the sale, the director now owns 6,433 shares of the company’s stock, valued at approximately $1,741,606.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $268.29, for a total value of $670,725.00. Following the completion of the sale, the chief financial officer now directly owns 40,029 shares in the company, valued at approximately $10,739,380.41. The disclosure for this sale can be found here. Insiders sold a total of 53,488 shares of company stock worth $14,600,474 in the last ninety days. 0.45% of the stock is owned by corporate insiders.
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Read More: Coverage Ratio
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.